Статті в журналах з теми "4CMenB"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "4CMenB".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Gönüllü, Erdem, Burcu Topçu, Naci Öner, Ahmet Soysal, and Metin Karaböcüoğlu. "Fever-Associated Supraventricular Tachycardia after 4CMenB Vaccination in an Infant." Case Reports in Pediatrics 2019 (September 22, 2019): 1–3. http://dx.doi.org/10.1155/2019/4591964.
Повний текст джерелаKent, Alison, Kazim Beebeejaun, Serena Braccio, Seilesh Kadambari, Paul Clarke, Paul T. Heath, and Shamez Ladhani. "Safety of meningococcal group B vaccination in hospitalised premature infants." Archives of Disease in Childhood - Fetal and Neonatal Edition 104, no. 2 (April 10, 2018): F171—F175. http://dx.doi.org/10.1136/archdischild-2017-314152.
Повний текст джерелаMarshall, Helen S., Prabha H. Andraweera, James Ward, John Kaldor, Ross Andrews, Kristine Macartney, Peter Richmond, et al. "An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol." Vaccines 10, no. 2 (February 16, 2022): 309. http://dx.doi.org/10.3390/vaccines10020309.
Повний текст джерелаYamashiro, Hirotaka, Nora Cutcliffe, Simon Dobson, David Fisman, and Ronald Gold. "The Role of Pediatricians as Key Stakeholders in Influencing Immunization Policy Decisions for the Introduction of Meningitis B Vaccine in Canada: The Ontario Perspective." Canadian Journal of Infectious Diseases and Medical Microbiology 26, no. 4 (2015): 183–90. http://dx.doi.org/10.1155/2015/963940.
Повний текст джерелаKimura, Alan, Daniela Toneatto, Annett Kleinschmidt, Huajun Wang, and Peter Dull. "Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates." Clinical and Vaccine Immunology 18, no. 3 (December 22, 2010): 483–86. http://dx.doi.org/10.1128/cvi.00304-10.
Повний текст джерелаIsitt, Catherine, Catherine A. Cosgrove, Mary Elizabeth Ramsay, and Shamez N. Ladhani. "Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience." Archives of Disease in Childhood 105, no. 8 (February 6, 2020): 784–90. http://dx.doi.org/10.1136/archdischild-2019-318047.
Повний текст джерелаLucidarme, Jay, Stefanie Gilchrist, Lynne S. Newbold, Stephen J. Gray, Edward B. Kaczmarski, Lynne Richardson, Julia S. Bennett, Martin C. J. Maiden, Jamie Findlow, and Ray Borrow. "Genetic Distribution of Noncapsular Meningococcal Group B Vaccine Antigens in Neisseria lactamica." Clinical and Vaccine Immunology 20, no. 9 (June 26, 2013): 1360–69. http://dx.doi.org/10.1128/cvi.00090-13.
Повний текст джерелаNolan, Terry, Hartley Garfield, Anil Gupta, Murdo Ferguson, Helen Marshall, Diego D’Agostino, and Daniela Toneatto. "Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults." Open Forum Infectious Diseases 4, suppl_1 (2017): S322. http://dx.doi.org/10.1093/ofid/ofx163.757.
Повний текст джерелаAzzari, Chiara, Maria Moriondo, Francesco Nieddu, Valentina Guarnieri, Lorenzo Lodi, Clementina Canessa, Giuseppe Indolfi, et al. "Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)." Vaccines 8, no. 3 (August 22, 2020): 469. http://dx.doi.org/10.3390/vaccines8030469.
Повний текст джерелаSoler-Garcia, Aleix, Mariona Fernández de Sevilla, Raquel Abad, Cristina Esteva, Laia Alsina, Julio Vázquez, Carmen Muñoz-Almagro, and Antoni Noguera-Julian. "Meningococcal Serogroup B Disease in Vaccinated Children." Journal of the Pediatric Infectious Diseases Society 9, no. 4 (October 21, 2019): 454–59. http://dx.doi.org/10.1093/jpids/piz071.
Повний текст джерелаLadhani, Shamez N., Ray Borrow, and Nick J. Andrews. "Growing evidence supports 4CMenB effectiveness." Lancet Infectious Diseases 18, no. 4 (April 2018): 370–71. http://dx.doi.org/10.1016/s1473-3099(18)30051-3.
Повний текст джерелаNolan, Terry, Miguel O’Ryan, María Elena Santolaya, Ferdinandus De Looze, Helen Marshall, Peter Richmond, Sam Henein, et al. "152. Protective Antibody Levels 7.5 Years After Primary Vaccination in Adolescence With a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults: Phase IIIb Clinical Findings." Open Forum Infectious Diseases 5, suppl_1 (November 2018): S11. http://dx.doi.org/10.1093/ofid/ofy209.022.
Повний текст джерелаFerrara, Pietro, Lucia Stromillo, and Luciana Albano. "Awareness, Attitudes, and Practices Toward Meningococcal B Vaccine among Pediatricians in Italy." Medicina 54, no. 6 (December 3, 2018): 100. http://dx.doi.org/10.3390/medicina54060100.
Повний текст джерелаBanzhoff, Angelika. "Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States." Therapeutic Advances in Vaccines 5, no. 1 (January 6, 2017): 3–14. http://dx.doi.org/10.1177/2051013616681365.
Повний текст джерелаMarshall, Helen S., Mark McMillan, Ann Koehler, Andrew Lawrence, Jenny M. MacLennan, Martin C. J. Maiden, Mary Ramsay, et al. "B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage ofNeisseria meningitidisin adolescents." BMJ Open 8, no. 7 (July 2018): e020988. http://dx.doi.org/10.1136/bmjopen-2017-020988.
Повний текст джерелаZafack, Joseline Guetsop, Alexandre Bureau, Danuta M. Skowronski, and Gaston De Serres. "Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials." BMJ Open 9, no. 5 (May 17, 2019): e026953. http://dx.doi.org/10.1136/bmjopen-2018-026953.
Повний текст джерелаLa Fauci, Vincenza, Daniela Lo Giudice, Raffaele Squeri, and Cristina Genovese. "Insight into Prevention of Neisseria Gonorrhoeae: A Short Review." Vaccines 10, no. 11 (November 18, 2022): 1949. http://dx.doi.org/10.3390/vaccines10111949.
Повний текст джерелаBasta, Nicole E., and Hannah Christensen. "4CMenB vaccine effectiveness: reasons for optimism." Lancet 388, no. 10061 (December 2016): 2719–21. http://dx.doi.org/10.1016/s0140-6736(16)32061-x.
Повний текст джерелаBiolchi, Alessia, Sara Tomei, Laura Santini, Rita La Gaetana, Elena Mori, Patricia Novy, Rino Rappuoli, et al. "7. Two-Dose 4CMenB Vaccination in Adolescents Elicits a Bactericidal Activity against 15 Outbreak-Representative Meningococcal Strains." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S26. http://dx.doi.org/10.1093/ofid/ofaa439.052.
Повний текст джерелаLeduc, Isabelle, Kristie L. Connolly, Afrin Begum, Knashka Underwood, Stephen Darnell, William M. Shafer, Jacqueline T. Balthazar, et al. "The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae." PLOS Pathogens 16, no. 12 (December 8, 2020): e1008602. http://dx.doi.org/10.1371/journal.ppat.1008602.
Повний текст джерелаDomnich, Alexander, Roberto Gasparini, Daniela Amicizia, Giuseppe Boccadifuoco, Marzia Monica Giuliani, and Donatella Panatto. "Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes." Journal of Immunology Research 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/353461.
Повний текст джерелаTaha, Muhamed-Kheir, and Ala-Eddine Deghmane. "Meningococcal carriage: the dilemma of 4CMenB vaccine." Lancet 384, no. 9960 (December 2014): 2088–90. http://dx.doi.org/10.1016/s0140-6736(14)60935-1.
Повний текст джерелаFagnocchi, Luca, Alessia Biolchi, Francesca Ferlicca, Giuseppe Boccadifuoco, Brunella Brunelli, Sébastien Brier, Nathalie Norais, et al. "Transcriptional Regulation of thenadAGene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine." Infection and Immunity 81, no. 2 (December 10, 2012): 560–69. http://dx.doi.org/10.1128/iai.01085-12.
Повний текст джерелаLangereis, Jeroen D., Bryan van den Broek, Sjoerd Franssen, Irma Joosten, Nicole M. A. Blijlevens, Marien I. de Jonge, and Saskia Langemeijer. "Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients." Blood Advances 4, no. 15 (August 7, 2020): 3615–20. http://dx.doi.org/10.1182/bloodadvances.2020002497.
Повний текст джерелаDubé, Eve, Dominique Gagnon, Denis Hamel, Sylvie Belley, Hélène Gagné, Nicole Boulianne, Monique Landry, and Julie A. Bettinger. "Parents’ and Adolescents’ Willingness to be Vaccinated Against Serogroup B Meningococcal Disease during a Mass Vaccination in Saguenay–Lac-St-Jean (Quebec)." Canadian Journal of Infectious Diseases and Medical Microbiology 26, no. 3 (2015): 163–67. http://dx.doi.org/10.1155/2015/732464.
Повний текст джерелаEsposito, Susanna, Claudia Tagliabue, and Samantha Bosis. "Meningococcal B Vaccination (4CMenB) in Infants and Toddlers." Journal of Immunology Research 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/402381.
Повний текст джерелаDonzelli, Alberto, and Piergiorgio Duca. "4CMenB safety and persistence of protection are unsatisfactory." Lancet Infectious Diseases 18, no. 6 (June 2018): 599–600. http://dx.doi.org/10.1016/s1473-3099(18)30271-8.
Повний текст джерелаHolmes, David. "UK poised to make decision on 4CMenB vaccine." Lancet Infectious Diseases 14, no. 3 (March 2014): 192–93. http://dx.doi.org/10.1016/s1473-3099(13)70345-1.
Повний текст джерелаBeck, Ekkehard, Johan Klint, Stephanie Garcia, Victoria Abbing, Veronique Abitbol, Orjan Akerborg, Lorenzo Argante, et al. "Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England." Vaccine 38, no. 47 (November 2020): 7558–68. http://dx.doi.org/10.1016/j.vaccine.2020.08.007.
Повний текст джерелаGarcia, Yara Ruiz, Woo-Yun Sohn, Mariagrazia Pizza, and Rafik Bekkat-Berkani. "02. Beyond B Antigen Coverage: The Potential of the 4CMenB Vaccine for Cross-protection Against Pathogenic Neisseria Infections." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S125. http://dx.doi.org/10.1093/ofid/ofab466.205.
Повний текст джерелаCarr, Jeremy, Emma Plested, Parvinder Aley, Susana Camara, Kimberly Davis, Jenny M. MacLennan, Steve Gray, et al. "‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents." BMJ Open 10, no. 10 (October 2020): e037358. http://dx.doi.org/10.1136/bmjopen-2020-037358.
Повний текст джерелаChannon-Wells, Samuel William, Emily Tough, Neda So, Daniel O'Connor, and Matthew D. Snape. "Differentiating vaccine reactions from invasive bacterial infections in young infants presenting to the emergency department in the 4CMenB era: a retrospective observational comparison." BMJ Paediatrics Open 6, no. 1 (October 2022): e001559. http://dx.doi.org/10.1136/bmjpo-2022-001559.
Повний текст джерелаLamoudi, Maya, Faye Baxter, Amarpal Bilkhu, and Claire Hathorn. "4CMenB and post-immunisation fever: an emerging hot topic." Archives of Disease in Childhood 103, no. 10 (January 27, 2018): 1002–3. http://dx.doi.org/10.1136/archdischild-2017-314645.
Повний текст джерелаAbad, Raquel, and Julio Vazquez. "Should we continue to monitor 4CMenB coverage with MATS?" Lancet Infectious Diseases 17, no. 7 (July 2017): 681–83. http://dx.doi.org/10.1016/s1473-3099(17)30174-3.
Повний текст джерелаRose, Warren E. "Meningococcal serogroup B outbreaks and use of 4CMenB vaccine." Journal of the American Pharmacists Association 54, no. 2 (March 2014): 198–201. http://dx.doi.org/10.1331/japha.2014.14512.
Повний текст джерелаLaw, Dennis K. S., Jianwei Zhou, Saul Deng, Linda Hoang, Gregory Tyrrell, Greg Horsman, John Wylie, and Raymond S. W. Tsang. "Determination of serotyping antigens, clonal analysis and genetic characterization of the 4CMenB vaccine antigen genes in invasive Neisseria meningitidis from Western Canada, 2009 to 2013." Journal of Medical Microbiology 63, no. 11 (November 1, 2014): 1490–99. http://dx.doi.org/10.1099/jmm.0.079921-0.
Повний текст джерелаEsposito, Susanna, and Nicola Principi. "Vaccine profile of 4CMenB: a four-componentNeisseria meningitidisserogroup B vaccine." Expert Review of Vaccines 13, no. 2 (January 6, 2014): 193–202. http://dx.doi.org/10.1586/14760584.2014.874949.
Повний текст джерелаHernández-García, Ignacio, Silvio Ragozzino, and Teresa Giménez-Júlvez. "Characteristics of YouTube videos about the meningococcal B vaccine (4CMenB)." Human Vaccines & Immunotherapeutics 16, no. 10 (March 2, 2020): 2513–17. http://dx.doi.org/10.1080/21645515.2020.1726683.
Повний текст джерелаManzoli, Lamberto, and Maria Elena Flacco. "4CMenB safety and persistence of protection are unsatisfactory – Authors' reply." Lancet Infectious Diseases 18, no. 6 (June 2018): 600–601. http://dx.doi.org/10.1016/s1473-3099(18)30282-2.
Повний текст джерелаMarshall, H. S., A. P. Koehler, B. Wang, M. A'Houre, M. Gold, H. Quinn, N. Crawford, N. Pratt, T. R. Sullivan, and K. Macartney. "Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia." Vaccine 38, no. 37 (August 2020): 5914–22. http://dx.doi.org/10.1016/j.vaccine.2020.07.009.
Повний текст джерелаCastilla, Jesús, Manuel García Cenoz, Raquel Abad, Laura Sánchez-Cambronero, Nicola Lorusso, Conchita Izquierdo, Soledad Cañellas Llabrés, et al. "Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children." New England Journal of Medicine 388, no. 5 (February 2, 2023): 427–38. http://dx.doi.org/10.1056/nejmoa2206433.
Повний текст джерелаSimões, Maria João, Célia Bettencourt, Rosita De Paola, Maria Giuliani, Mariagrazia Pizza, Monica Moschioni, and Jorge Machado. "Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal." PLOS ONE 12, no. 5 (May 1, 2017): e0176177. http://dx.doi.org/10.1371/journal.pone.0176177.
Повний текст джерелаLadhani, Shamez N., Nick Andrews, Sydel R. Parikh, Helen Campbell, Joanne White, Michael Edelstein, Xilian Bai, Jay Lucidarme, Ray Borrow, and Mary E. Ramsay. "Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England." New England Journal of Medicine 382, no. 4 (January 23, 2020): 309–17. http://dx.doi.org/10.1056/nejmoa1901229.
Повний текст джерелаTenenbaum, T. "Meningokokken-Impfung." Kinder- und Jugendmedizin 14, no. 01 (2014): 22–25. http://dx.doi.org/10.1055/s-0038-1629369.
Повний текст джерелаAbad, R., A. Biolchi, M. Moschioni, M. M. Giuliani, M. Pizza, and J. A. Vázquez. "A Large Portion of Meningococcal Antigen Typing System-Negative Meningococcal Strains from Spain Is Killed by Sera from Adolescents and Infants Immunized with 4CMenB." Clinical and Vaccine Immunology 22, no. 4 (January 28, 2015): 357–60. http://dx.doi.org/10.1128/cvi.00669-14.
Повний текст джерелаLongtin, Jean, Rejean Dion, Marc Simard, Jean-Francois Betala Belinga, Yves Longtin, Brigitte Lefebvre, Annie-Claude Labbé, Genevieve Deceuninck, and Philippe De Wals. "Possible Impact of Wide-scale Vaccination Against Serogroup B Neisseria Meningitidis on Gonorrhea Incidence Rates in One Region of Quebec, Canada." Open Forum Infectious Diseases 4, suppl_1 (2017): S734—S735. http://dx.doi.org/10.1093/ofid/ofx180.002.
Повний текст джерелаMcMillan, Mark, Helen S. Marshall, and Peter Richmond. "4CMenB vaccine and its role in preventing transmission and inducing herd immunity." Expert Review of Vaccines 21, no. 1 (November 29, 2021): 103–14. http://dx.doi.org/10.1080/14760584.2022.2003708.
Повний текст джерелаHarrison, Lee H., and David S. Stephens. "Good News and Bad News — 4CMenB Vaccine for Group B Neisseria meningitidis." New England Journal of Medicine 382, no. 4 (January 23, 2020): 376–78. http://dx.doi.org/10.1056/nejme1916440.
Повний текст джерелаRappuoli, Rino, Mariagrazia Pizza, Vega Masignani, and Kumaran Vadivelu. "Meningococcal B vaccine (4CMenB): the journey from research to real world experience." Expert Review of Vaccines 17, no. 12 (December 2, 2018): 1111–21. http://dx.doi.org/10.1080/14760584.2018.1547637.
Повний текст джерелаMedini, Duccio, Maria Stella, and James Wassil. "MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine." Vaccine 33, no. 23 (May 2015): 2629–36. http://dx.doi.org/10.1016/j.vaccine.2015.04.015.
Повний текст джерела